🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07357415
Active, not recruiting Phase 3

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

NCT07357415 · tracked via the Priya Life Science USA tracker
Sponsor
Eli Lilly and Company
Phase
Phase 3
Started
2026-01-24
Last updated
2026-06-09

Condition(s) studied

ObesityOverweight

Investigational drug(s) / intervention(s)

Retatrutide

Retatrutide: Administered SC

Study summary

The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Have a Body Mass Index (BMI) at screening * ≥ 30 kilogram per square meter (kg/m2) OR * ≥ 27 kg/m2 with presence of at least one of the following weight-related conditions at screening: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease * Have at least one unsuccessful attempt to lose weight by dieting Exclusion Criteria: * Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days before screening * Have a prior or planned surgical treatment for obesity * Have type 1 diabetes or type 2 diabetes * Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) * Have had within the past 90 days before screening: * heart attack * stroke * hospitalization for unstable angina or heart failure * Have New York Heart Association Functional Classification Class IV congestive heart failure * Have a history of chronic or acute pancreatitis * Have taken weight loss drugs, including over-the counter medications within 90 days prior to screening

Primary outcome measure(s)

Trial sites (35)

FacilityCityRegionStatus
Arizona Research Center Phoenix Arizona
Care Access - Huntington Beach Huntington Beach California
Los Angeles Institute for Metabolic Research Los Angeles California
New Horizon Research Center Miami Florida
Encore Medical Research - Weston Weston Florida
Pacific Diabetes & Endocrine Center Honolulu Hawaii
Monroe Biomedical Research - Louisville Louisville Kentucky
Brigham and Women's Hospital Diabetes Program Boston Massachusetts
Great Lakes Research Group, Inc. Bay City Michigan
NYC Research INC Long Island City New York
Weill Cornell Medical College New York New York
Care Access - Raleigh Raleigh North Carolina
New Phase Research and Development Knoxville Tennessee
Velocity Clinical Research, Dallas Dallas Texas
Cedar Health Research - Texas Native Health Dallas Texas
Cedar Health Research Dallas Texas
Cedar Health Research - Fort Worth Fort Worth Texas
Advanced Research Institute Ogden Utah
Dominion Medical Associates, Inc. Richmond Virginia
CAMC Institute for Academic Medicine Charleston West Virginia
Cicemo Srl Buenos Aires Argentina
CARDIAMET Investigaciones Médicas Buenos Aires Argentina
Stat Research S.A. Buenos Aires Argentina
Centro de Investigaciones Metabólicas (CINME) Buenos Aires Argentina
Centro Médico Viamonte Buenos Aires Argentina
Aggarwal and Associates Limited Brampton Canada
Med Trust Research Courtice Canada
Winterberry Research Inc. Hamilton Canada
Diex Recherche Inc. Division Joliette Joliette Canada
Milestone Research Inc. London Canada
Diex Recherche Inc. Division Quebec Québec Canada
Diex Recherche Inc. Division Sherbrooke Sherbrooke Canada
Canadian Phase Onward Toronto Canada
Dr. Anil K. Gupta Medicine Professional Corporation Toronto Canada
C.I.C. Mauricie inc. Trois-Rivières Canada

More Eli Lilly and Company trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07357415 on ClinicalTrials.gov ↗ ← All trials in the USA